Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer.

Literature DB >> 23564483

Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer.

Xin-yan Wang¹, Hai-jiao Wang, Xiu-qin Li.

Abstract

We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient's specimens were taken at the time of surgery. Determination of resistance is based on whether first diagnosis of relapse occurred within 6 months after the cessation of chemotherapy. PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. PRX III may be associated with drug resistance in ovarian cancer.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23564483 DOI： 10.1007/s13277-013-0769-0

Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283

37 in total

1. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes.

Authors: H Z Chae; K Robison; L B Poole; G Church; G Storz; S G Rhee
Journal: Proc Natl Acad Sci U S A Date: 1994-07-19 Impact factor: 11.205

2. Increased expression of peroxiredoxin II confers resistance to cisplatin.

Authors: Y M Chung; Y D Yoo; J K Park; Y T Kim; H J Kim
Journal: Anticancer Res Date: 2001 Mar-Apr Impact factor: 2.480

3. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation.

Authors: Diane R Wonsey; Karen I Zeller; Chi V Dang
Journal: Proc Natl Acad Sci U S A Date: 2002-05-14 Impact factor: 11.205

4. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas.

Authors: Joon Hyuk Choi; Tae Nyeun Kim; Seongyong Kim; Suk-Hwan Baek; Jung Hye Kim; Seung Rock Lee; Jae-Ryong Kim
Journal: Anticancer Res Date: 2002 Nov-Dec Impact factor: 2.480

5. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma.

Authors: Xiu-Qin Li; Shu-Lan Zhang; Zhen Cai; Yuan Zhou; Tian-Min Ye; Jen-Fu Chiu
Journal: Cancer Lett Date: 2008-12-03 Impact factor: 8.679

6. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.

Authors: Xiaojuan Yan; Michael Fraser; Qing Qiu; Benjamin K Tsang
Journal: Gynecol Oncol Date: 2006-03-20 Impact factor: 5.482

7. Peroxiredoxins, a novel protein family in lung cancer.

Authors: Siri T Lehtonen; Anne-Mari Svensk; Ylermi Soini; Paavo Pääkkö; Pasi Hirvikoski; Sang Won Kang; Marjaana Säily; Vuokko L Kinnula
Journal: Int J Cancer Date: 2004-09-10 Impact factor: 7.396

Review 8. Structure, mechanism and regulation of peroxiredoxins.

Authors: Zachary A Wood; Ewald Schröder; J Robin Harris; Leslie B Poole
Journal: Trends Biochem Sci Date: 2003-01 Impact factor: 13.807

9. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.

Authors: Changyi Quan; Eun-Jong Cha; Hyung-Lae Lee; Kwang Hee Han; Keon Myung Lee; Wun-Jae Kim
Journal: J Urol Date: 2006-04 Impact factor: 7.450

10. Epithelial-mesenchymal transition in ovarian carcinoma.

Authors: Ben Davidson; Claes G Tropé; Reuven Reich
Journal: Front Oncol Date: 2012-04-10 Impact factor: 6.244

9 in total

Review 1. The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors: Lianqin Li; Ai-Qun Yu
Journal: J Cancer Res Clin Oncol Date: 2015-01-21 Impact factor: 4.553

2. Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells.

Authors: Y-G Wang; L Li; C-H Liu; S Hong; M-J Zhang
Journal: Clin Transl Oncol Date: 2013-10-09 Impact factor: 3.405

3. Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.

Authors: Chengyao Xie; Yong Han; Lin Fu; Qingchang Li; Xueshan Qiu; Enhua Wang
Journal: Tumour Biol Date: 2014-05-16

4. Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients.

Authors: LingLong Peng; Rong Wang; JingKun Shang; YongFu Xiong; ZhongXue Fu
Journal: Oncotarget Date: 2017-02-28

5. Comparative mitochondrial proteomic analysis of human large cell lung cancer cell lines with different metastasis potential.

Authors: Zhenkun Liu; Song Xu; Lu Li; Xiaorong Zhong; Chun Chen; Yaguang Fan; Wang Shen; Lingling Zu; Feng Xue; Min Wang; Qinghua Zhou
Journal: Thorac Cancer Date: 2019-04-04 Impact factor: 3.500